Details for Patent: 7,407,955

Title:	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
Abstract:	The present invention relates to substituted xanthines of general formula ##STR00001## wherein R.sup.1 to R.sup.3 are defined as in claims 1 to 16, the tautomers, the stereoisomers, the mixtures, the prodrugs thereof and the salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on the activity of the enzyme dipeptidylpeptidase-IV (DPP-IV).
Inventor(s):	Himmelsbach; Frank (Mittelbiberach, DE), Langkopf; Elke (Warthausen, DE), Eckhardt; Matthias (Biberach, DE), Mark; Michael (Biberach, DE), Maier; Roland (Biberach, DE), Lotz; Ralf R. H. (Schemmerhofen, DE), Tadayyon; Mohammad (Ulm, DE)
Assignee:	Boehringer Ingelheim Pharma GmbH & Co., KG (Ingelheim, DE)
Filing Date:	Aug 12, 2003
Application Number:	10/639,036
Claims:	1. A compound chosen from: (1) 1-[(quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3-amino-pipe- ridin-1-yl)-xanthine, (2) 1-(2-{2-[(ethylaminocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(2-- butyn-1-yl)-8-((R)-3-amino-piperidin-1-yl)-xanthine, (3) 1-(2-{2-[(methylaminocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(2- -butyn-1-yl)-8-((R)-3-amino-piperidin-1-yl)-xanthine, (4) 1-(2-phenyl-2-oxo-ethyl)-3-methyl-7-((E)-2-buten-1-yl)-8-((R)-3-amino-pip- eridin-1-yl)-xanthine, (5) 1-[(3-methyl-isoquinolin-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-((S)-3-- amino-piperidin-1-yl)-xanthine, (6) 1-[(3-methyl-isoquinolin-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3-- amino-piperidin-1-yl)-xanthine, (7) 1-[(4-methyl-isoquinolin-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-((S)-3-- amino-piperidin-1-yl)-xanthine, (8) 1-[(4-methyl-isoquinolin-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3-- amino-piperidin-1-yl)-xanthine, (9) 1-[2-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-2-oxo-ethyl]-3-methyl-7-(2-butyn- -1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine, (10) 1-[(4-methoxy-naphthalen-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-((S)-3-- amino-piperidin-1-yl)-xanthine, (11)-[(4-methoxy-naphthalen-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)- -3-amino-piperidin-1-yl)-xanthine, (12) 1-[2-(benzo[1,3]dioxol-4-yl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-((R- )-3-amino-piperidin-1-yl)-xanthine, (13) 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-a- mino-piperidin-1-yl)-xanthine, (14) 1-(2-{2-[(methylaminocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-((- E)-2-buten-1-yl)-8-((R)-3-amino-piperidin-1-yl)-xanthine, (15) 1-(2-{2-[(methylaminocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-((- E)-2-buten-1-yl)-8-((S)-3-amino-piperidin-1-yl)-xanthine, (16) 1-(2-{2-[(isopropylcarbonyl)amino]-phenyl}-2-oxo-ethyl)-3-methyl-7-(2-but- yn-1-yl)-8-((R)-3-amino-piperidin-1-yl)-xanthine, (17) 1-[(4-cyano-naphthalen-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3-am- ino-piperidin-1-yl)-xanthine, (18) 1-[(4-phenyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3-a- mino-piperidin-1-yl)-xanthine, (19) 1-[(8-methyl-quinoxalin-6-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3-a- mino-piperidin-1-yl)-xanthine, (20) 1-[(4-fluoro-naphthalen-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3-a- mino-piperidin-1-yl)-xanthine, (21) 1-((E)-3-pentafluorophenyl-allyl)-3-methyl-7-(2-butyn-1-yl)-8-((R)-3-amin- o-piperidin-1-yl)-xanthine, (22) 1-[(3-trifluoromethyl-isoquinolin-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-- 8-((R)-3-amino-piperidin-1-yl)-xanthine, (23) 1-[(3-difluoromethyl-isoquinolin-1-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8- -((R)-3-amino-piperidin-1-yl)-xanthine, (24) 1-[2-(biphenyl-2-yl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3-amin- o-piperidin-1-yl)-xanthine, (25) 1-[(3-methyl-isoquinolin-1-yl)methyl]-3-cyclopropyl-7-(2-butyn-1-yl)-8-((- R)-3-amino-piperidin-1-yl)-xanthine, (26) 1-[2-(3-methoxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(2-butyn-1-yl)-8-((R)-3-a- mino-piperidin-1-yl)-xanthine, (27) 1-[(3-methyl-isoquinolin-1-yl)methyl]-3-methyl-7-(2-chloro-benzyl)-8-((R)- -3-amino-piperidin-1-yl)-xanthine and (28) 1-[(3-methyl-isoquinolin-1-yl)methyl]-3-methyl-7-(2-bromo-benzyl)-8-((R)-- 3-amino-piperidin-1-yl)-xanthine or tautomers, enantiomers, diastereomers, mixtures thereof or salts thereof. 2. A compound chosen from: (1) 1-(2-cyano-ethyl)-3-methyl-7-(2-cyano-benzyl)-8-(3-amino-piperidin-1-yl)-- xanthine, (2) 1-(2-{2-[(ethoxycarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3-meth- yl-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, (3) 1-(2-{2-[(aminocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3-methy- l-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, (4) 1-(2-{3-[(methanesulphinyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3-me- thyl-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, (5) 1-(1-methyl-2-oxo-2-phenyl-ethyl)-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3- -amino-piperidin-1-yl)-xanthine, (6) 1-(2-phenoxy-ethyl)-3-methyl-7-(2-cyano-benzyl)-8-(3-amino-piperidin-1-yl- )-xanthine, (7) 1-(2-phenyl-2-oxo-ethyl)-7-(3-methyl-2-buten-1-yl)-8-(3-amino-piperidin-1- -yl)-xanthine, (8) 1-(2-{3-[(ethoxycarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3-meth- yl-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, (9) 1-(2-{2-[(methylaminocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3- -methyl-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, (10) 1-(2-{2-[(dimethylaminocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-- (3-methyl-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, (11) 1-(2-methoxy-ethyl)-3-methyl-7-(2-cyano-benzyl)-8-(3-amino-piperidin-1-yl- )-xanthine, (12) 1-methyl-3-[(methoxycarbonyl)methyl]-7-(2-cyano-benzyl)-8-(3-amino-piperi- din-1-yl)-xanthine, (13) 1-methyl-3-cyanomethyl-7-(2-cyano-benzyl)-8-(3-amino-piperidin-1-yl)-xant- hine, (14) 1-methyl-3-(2-propyn-1-yl)-7-(2-cyano-benzyl)-8-(3-amino-piperi- din-1-yl)-xanthine, (15)-{2-[3-(2-oxo-imidazolidin-1-yl)-phenyl]-2-oxo-ethyl}-3-methyl-7-(3-m- ethyl-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, (16) 1-methyl-3-(2-propen-1-yl)-7-(2-cyano-benzyl)-8-(3-amino-piperidin-1-yl)-- xanthine, (17) 1-(2-{2-[(ethylcarbonyl)amino]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3-methyl-- 2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, (18) 1-methyl-3-phenyl-7-(2-cyano-benzyl)-8-(3-amino-piperidin-1-yl)-xanthine, (19) 1-[2-(2-amino-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl- )-8-((S)-3-amino-piperidin-1-yl)-xanthine, (20) 1-(2-phenyl-2-oxo-ethyl)-3-cyanomethyl-7-(3-methyl-2-buten-1-yl)-8-(3-ami- no-piperidin-1-yl)-xanthine, (21) 1-[(quinolin-2-yl)methyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-amino-p- iperidin-1-yl)-xanthine, (22) 1-[(2-oxo-2H-chromen-4-yl)methyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3- -amino-piperidin-1-yl)-xanthine, (23) 1-[(cinnolin-4-yl)methyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-amino-p- iperidin-1-yl)-xanthine, (24) 1-[(1-methyl-2-oxo-1,2-dihydro-quinolin-4-yl)methyl]-3-methyl-7-(3-methyl- -2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, (25) 1-[(4-oxo-3,4-dihydro-phthalazin-1-yl)methyl]-3-methyl-7-(3-methyl-2-bute- n-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, (26) 1-[(quinazolin-4-yl)methyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-amino- -piperidin-1-yl)-xanthine, (27) 1-[(5-methyl-3-phenyl-isoxazol-4-yl)methyl]-3-methyl-7-(3-methyl-2-buten-- 1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, (28) 1-[(isoquinolin-3-yl)methyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-amin- o-piperidin-1-yl)-xanthine, (29) 1-[(3-phenyl-[1,2,4]oxadiazol-5-yl)methyl]-3-methyl-7-(3-methyl-2-buten-1- -yl)-8-(3-amino-piperidin-1-yl)-xanthine, (30) 1-[(4-phenyl-pyridin-2-yl)methyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3- -amino-piperidin-1-yl)-xanthine, (31) 1-[(5-phenyl-pyridin-2-yl)methyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3- -amino-piperidin-1-yl)-xanthine, (32) 1-[(3-methyl-4-oxo-3,4-dihydro-phthalazin-1-yl)methyl]-3-methyl-7-(3-meth- yl-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, (33) 1-[2-(3-methylsulphanyl-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten- -1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, (34) 1-[2-(3-methanesulphinyl-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-bute- n-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, (35) 1-[2-(3-methanesulphonyl-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-bute- n-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, (36) 1-[2-(3-carboxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8- -(3-amino-piperidin-1-yl)-xanthine, (37) 1-[2-(3-methoxycarbonyl-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten- -1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, (38)-{2-[3-(methylaminocarbonyl)-phenyl]-2-oxo-ethyl}-3-methyl-7-(3-methy- l-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, (39) 1-{2-[3-(dimethylaminocarbonyl)-phenyl]-2-oxo-ethyl}-3-methyl-7-(3-methyl- -2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, (40) 1-{2-[3-(morpholin-4-yl-carbonyl)-phenyl]-2-oxo-ethyl}-3-methyl-7-(3-meth- yl-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, (41) 1-[2-(2-carboxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8- -(3-amino-piperidin-1-yl)-xanthine, (42) 1-[2-(2-ethoxycarbonyl-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-- 1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, (43) 1-{2-[2-(dimethylaminocarbonyl)-phenyl]-2-oxo-ethyl}-3-methyl-7-(3-methyl- -2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, (44) 1-{2-[2-(morpholin-4-yl-carbonyl)-phenyl]-2-oxo-ethyl}-3-methyl-7-(3-meth- yl-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, (45) 1-[2-(2,6-dimethoxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-y- l)-8-(3-amino-piperidin-1-yl)-xanthine, (46) 1-((E)-3-phenyl-allyl)-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-amino-pipe- ridin-1-yl)-xanthine, (47) 1-[(benzo[b]thiophen-3-yl)methyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3- -amino-piperidin-1-yl)-xanthine, (48) 1-[(1H-indol-3-yl)methyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-amino-p- iperidin-1-yl)-xanthine, (49) 1-[(biphenyl-4-yl)methyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-amino-p- iperidin-1-yl)-xanthine, (50) 1-(2-cyclohexyl-2-oxo-ethyl)-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-amin- o-piperidin-1-yl)-xanthine, (51) 1-(3,3-dimethyl-2-oxo-butyl)-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-amin- o-piperidin-1-yl)-xanthine, (52) 1-({5-[(methoxycarbonyl)methylamino]-isoquinolin-1-yl}methyl)-3-methyl-7-- (3-methyl-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, (53) 1-(2-dimethylamino-2-oxo-ethyl)-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(3-a- mino-piperidin-1-yl)-xanthine, (54) 1-[2-(piperidin-1-yl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-(- 3-amino-piperidin-1-yl)-xanthine, (55) 1-[(2-methyl-1-oxo-1,2-dihydro-isoquinolin-4-yl)methyl]-7-(3-methyl-2-but- en-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, (56) 1-[2-(2,3-dimethoxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-y- l)-8-(3-amino-piperidin-1-yl)-xanthine, (57) 1-[2-(pyrrolidin-1-yl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-yl)-8-- (3-amino-piperidin-1-yl)-xanthine, (58) 1-[2-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-2-oxo-ethyl]-3-methyl-7-(3-methy- l-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, (59) 1-[2-(3-methyl-2-oxo-2,3-dihydro-benzooxazol-7-yl)-2-oxo-ethyl]-3-methyl-- 7-(3-methyl-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, (60) 1-[2-(benzo[1,3]dioxol-4-yl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-- yl)-8-(3-amino-piperidin-1-yl)-xanthine, (61) 1-methyl-3-isopropyl-7-(2-cyano-benzyl)-8-(3-amino-piperidin-1-yl)-xanthi- ne, (62) 1-[2-(2-cyanomethylamino-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methy- l-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, (63) 1-[(isoquinolin-1-yl)methyl]-3-[(methoxycarbonyl)methyl]-7-(3-methyl-2-bu- ten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, (64) 1-(2-{2-[(isopropyloxycarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(- 3-methyl-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, (65) 1-[2-(2-{[(ethoxycarbonylamino)carbonyl]amino}-phenyl)-2-oxo-ethyl]-3-met- hyl-7-(3-methyl-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, (66) 1-[2-(2-acetylamino-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-1-y- l)-8-((S)-3-amino-piperidin-1-yl)-xanthine, (67) 1-(2-{2-[(methylaminocarbonyl)methoxy]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3- -methyl-2-buten-1-yl)-8-((S)-3-amino-piperidin-1-yl)-xanthine, (68) 1-methyl-7-(2-cyano-benzyl)-8-(3-amino-piperidin-1-yl)-xanthine, (69) 1-(2-{2-[(isopropylcarbonyl)amino]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3-met- hyl-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, (70) 1-(2-{2-[(methoxycarbonyl)amino]-phenyl}-2-oxo-ethyl)-3-methyl-7-(3-methy- l-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, (71) 1-[2-(3-methyl-2-oxo-2,3-dihydro-benzooxazol-4-yl)-2-oxo-ethyl]-3-methyl-- 7-(3-methyl-2-buten-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, (72) 1-[2-(2-nitro-3-methoxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten- -1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, (73) 1-[2-(2-amino-3-methoxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten- -1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, (74) 1-[(3-methyl-isoquinolin-1-yl)methyl]-3-methyl-7-(3-methyl-1-buten-1-yl)-- 8-((R)-3-amino-piperidin-1-yl)-xanthine, (75) 1-[(3-methyl-isoquinolin-1-yl)methyl]-3-methyl-7-(2-cyano-benzyl)-8-(3-am- ino-piperidin-1-yl)-xanthine, (76) 1-[2-(3-carboxymethoxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-- 1-yl)-8-(3-amino-piperidin-1-yl)-xanthine and (77) 1-[2-(2-carboxymethoxy-phenyl)-2-oxo-ethyl]-3-methyl-7-(3-methyl-2-buten-- 1-yl)-8-(3-amino-piperidin-1-yl)-xanthine, or tautomers, enantiomers, diastereomers, mixtures thereof or the salts thereof. 3. A physiologically acceptable salt of a compound according to claim 1 or 2 with an inorganic or organic acid or base. 4. A pharmaceutical composition comprising a pharmaceutically acceptable amount of a compound according to claim 1 or 3 optionally together with one or more inert carriers and/or diluents. 5. A compound of formula (I) ##STR00006## wherein R.sup.1 is 4-methyl-2-quinazolinylmethyl; R.sup.2 is methyl; and R.sup.3 is 2-butyn-1-yl. 6. A pharmaceutical composition comprising one or more inert carriers or diluents and a compound of formula (I) ##STR00007## wherein R.sup.1 is 4-methyl-2-quinazolinylmethyl; R.sup.2 is methyl; and R.sup.3 is 2-butyn-1-yl. 7. A salt of a compound of formula (I) ##STR00008## wherein R.sup.1 is 4-methyl-2-quinazolinylmethyl; R.sup.2 is methyl; and R.sup.3 is 2-butyn-1-yl. 8. A physiologically acceptable salt of a compound of formula (I) ##STR00009## wherein R.sup.1 is 4-methyl-2-quinazolinylmethyl; R.sup.2 is methyl; and R.sup.3 is 2-butyn-1-yl. 9. A pharmaceutical composition comprising one or more inert carriers or diluents and a physiologically acceptable salt of a compound of formula (I) ##STR00010## wherein R.sup.1 is 4-methyl-2-quinazolinylmethyl; R.sup.2 is methyl; and R.sup.3 is 2-butyn-1-yl. 10. A salt of a compound of formula (I) ##STR00011## wherein R.sup.1 is 4-methyl-2-quinazolinylmethyl; R.sup.2 is methyl; and R.sup.3 is 2-butyn-1-yl, with an inorganic or organic acid. 11. A physiologically acceptable salt of a compound of formula (I) ##STR00012## wherein R.sup.1 is 4-methyl-2-quinazolinylmethyl; R.sup.2 is methyl; and R.sup.3 is 2-butyn-1-yl, with an inorganic or organic acid. 12. A pharmaceutical composition comprising one or more inert carriers or diluents and a physiologically acceptable salt of a compound of formula (I) ##STR00013## wherein R.sup.1 is 4-methyl-2-quinazolinylmethyl; R.sup.2 is methyl; and R.sup.3 is 2-butyn-1-yl, with an inorganic or organic acid. 13. The compound 1-[(4-methyl-quinazolin-2-yl) methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine of the formula ##STR00014## 14. A pharmaceutical composition comprising one or more inert carriers or diluents and the compound 1-[(4-methyl-quinazolin-2-yl) methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine of the formula ##STR00015## 15. A salt of the compound 1[(4-methyl-quinazolin-2-yl) methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine of the formula ##STR00016## 16. A physiologically acceptable salt of the compound 1-[(4-methyl-quinazolin-2-yl) methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine of the formula ##STR00017## 17. A pharmaceutical composition comprising one or more inert carriers or diluents and a physiologically acceptable salt of the compound 1-[(4-methyl-quinazolin-2-yl) methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine of the formula ##STR00018## 18. A salt of the compound 1-[(4-methyl-quinazolin-2-yl) methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl-xanthine of the formula ##STR00019## with an inorganic or organic acid. 19. A physiologically acceptable salt of the compound 1-[(4-methyl-quinazolin-2-yl) methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine of the formula ##STR00020## with an inorganic or organic acid. 20. A pharmaceutical composition comprising one or more inert carriers or diluents and a physiologically acceptable salt of the compound 1-[(4-methyl-quinazolin-2-yl) methyl]-3-methyl-7-(2-butyn-1yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine of the formula ##STR00021## with an inorganic or organic acid. 21. A pharmaceutical composition comprising a pharmaceutically acceptable amount of a physiologically acceptable salt according to claim 3, optionally together with one or more inert carriers and/or diluents.